Whole Brain Radiation Therapy for Treating Cerebral Metastasis May Not Be Necessary after Stereotactic Radiosurgery Performed with Magnetization-Prepared, Rapid-Acquisition Gradient Echo MRI with Triple-Dose Contrastdoi:10.1159/000062266B. YoungW.F. Regine...
1) and has established itself as an innovator in oncology, dedicated to improving the lives of people with cancer. Novocure milestones in brain cancer treatment. Novocure was founded in 2000 with a patient-forward approach that remains the centre of its corporate mission. The timeline highlights...
Newer options for treating drug-resistant (MDR+) cancer cells using photoradiation therapy. Gulati SC, Lemoli RM, Igarashi T and Atzpodien J: Newer options for treating drug-resistant (MDR+) cancer cells using photoradiation therapy. Leuk ... S C,Gulati,R M,... - 《Leukemia & Lymphoma...
Mechanisms and Therapy for Cancer Metastasis to the Brain Advances in chemotherapy and targeted therapies have improved survival in cancer patients with an increase of the incidence of newly diagnosed brain metast... F Franchino,R Rudà,R Soffietti - 《Frontiers in Oncology》 被引量: 3发表: 201...
Nanoparticles have many potential benefits for diagnosing and treating metastatic cancer, including the ability to transport complex molecular cargoes to the major sites of metastasis, such as the lungs, liver and lymph nodes, as well as targeting to specific cell populations within these organs. ...
High-grade glioma (HGG), a type of aggressive brain cancer, accounts for the leading cause of cancer-related mortality for children and adolescents. These cancers lack a therapeutic target, reducing viable treatment options. A recent study in Cancer Cell has determined upregulation of a protein...
s just sequential therapy. How do you manage some of our localized therapies in this, whether these would be debulking metastasectomies, SBRT [stereotactic body radiation therapy], other palliative radiation forms, using some of those localized therapies to try to debulk the cancer, take down ...
(a) an effective amount of EZH2 inhibitor, and (b) one or more second agents, or (2) contacting the cell with an effective amount of EZH2 inhibitor and exposing the cell to a radiation, wherein the cancer cell is an atypical teratoid rhabdoid tumor cell or a malignant rhabdoid tumor ...
The team tested the approach using patient-derived glioblastoma lines provided by the Biospecimen and Pathology Core of the UCLA SPORE in Brain Cancer. Quetiapine was identified in a screen of dopamine receptor antagonists for their ability to prevent phenotype conversion of non-tumorigenic glioblastoma ...
When used in mice with human glioblastoma, CD133-targetting CAR-T therapy was considered a success due to reduced tumour burden and improved survival. The data from this study has led to the formation of a new Hamilton-based start-up brain cancer immunotherapy company called Empirica Therapeutics...